Medtronic Raises Quarterly Dividend 1.4% to $0.72

Medtronic plc raised its quarterly dividend 1.4% to $0.72 per share from $0.71, lifting the annual dividend to $2.88. The higher rate first went ex-dividend on June 26, 2026, and the next ex-dividend date is September 25, 2026.

Why the dividend changed

Medtronic did not attribute the increase to a single transaction or temporary gain. The board approved the higher payment alongside fiscal 2026 results that management described as evidence of disciplined execution and portfolio strength. The company generated $7.3 billion of operating cash flow and $5.4 billion of free cash flow during the year, while returning $4.2 billion to shareholders. Revenue increased 8.4% as reported and 5.8% organically, although non-GAAP operating margin declined 130 basis points. That combination supports a continued dividend increase while helping explain why the step-up was limited to 1.4%. Medtronic’s fiscal 2026 results

The operating picture subsequently strengthened. In the first quarter of fiscal 2027, Medtronic reported revenue of $9.8 billion, an increase of 13.7% as reported and organically, and non-GAAP diluted earnings of $1.45 per share. It raised its fiscal 2027 organic revenue-growth guidance to 7.25% to 7.75% and its non-GAAP diluted earnings guidance to $5.94 to $6.00 per share. Chief Financial Officer Thierry Piéton cited strong operating performance and disciplined financial management as reasons the company exceeded expectations. Medtronic’s first-quarter fiscal 2027 results

A major portfolio change is also under way, but Medtronic did not present it as the reason for the June dividend increase. The company launched an exchange offer in September to complete the separation of MiniMed, its former diabetes business. Chief Executive Geoff Martha said the separation would allow Medtronic to focus capital allocation on its Cardiovascular, Neuroscience and Surgical portfolios. The transaction therefore affects the future business mix and capital-allocation framework rather than explaining the increase already declared. Medtronic’s MiniMed exchange-offer announcement

Dividend track record

The recent payment sequence shows a regular annual step-up rather than irregular increases. Quarterly payments were $0.70 through March 28, 2025, rose to $0.71 beginning with the June 27, 2025, ex-dividend date and reached $0.72 on June 26, 2026. The five-year annualized dividend-growth rate is 4.1%, but the latest increase is below that longer-term pace.

Full-year distributions rose from $2.28 per share in 2020 to $2.47 in 2021 and $2.67 in 2022. Growth then moderated: the annual total increased 3.0% to $2.75 in 2023, 1.5% to $2.79 in 2024 and 1.4% to $2.83 in 2025. The pattern is one of uninterrupted but progressively smaller increases. The last annual cut occurred in 2000.

Medtronic says the latest increase marked its 49th consecutive year of higher annual dividend payments, a longer company-reported record than the recent payment history alone establishes. The company also identifies itself as a member of the S&P 500 Dividend Aristocrats index. Medtronic’s latest quarterly dividend declaration

Is the dividend covered?

The dividend consumes 70% of earnings. That leaves less earnings retained than at a company with a lower payout ratio, but it still places the distribution below reported earnings rather than above them.

SmarterDividends rates the dividend A, with a safety score of 86. That grade means the dividend is considered very safe within the scoring range of 80 to 100. The assessment is consistent with Medtronic’s positive operating cash generation, long record of annual increases and continued earnings guidance, although the 70% payout ratio leaves coverage sensitive to sustained profit performance.

Yield and valuation

At a share price of $89.47, Medtronic’s forward yield is 3.23%. That compares with a 1.80% median forward yield for the Healthcare sector, giving the shares a higher income rate than the sector benchmark.

SmarterDividends estimates fair value at $92.36 and assigns a fair valuation verdict. The valuation assessment indicates that the 3.23% yield is attached to a share price broadly aligned with the estimate, rather than to a large measured valuation discount.

What to watch

The immediate calendar item is the September 25, 2026, ex-dividend date. Investors must own shares before the ex-dividend date to qualify under standard market settlement rules for that quarterly distribution.

The MiniMed separation is the more significant corporate event. Medtronic has offered to exchange at least 80.1% of MiniMed’s shares and expects the offer to expire on October 9, 2026, unless extended or terminated. Completion would sharpen Medtronic’s focus on its remaining medical-technology portfolios and alter the company’s share base if Medtronic shares are accepted in the exchange.

Operating performance also remains central to coverage. The relevant markers are progress against the raised fiscal 2027 revenue and earnings guidance, continued growth in cardiovascular and neuroscience products, and the integration of the Scientia Vascular and SPR Therapeutics acquisitions. Those items will show whether the earnings base supporting the $2.88 annual dividend is developing in line with management’s latest outlook.